Cytodyn Inc (CYDY)

[Borel Fields]

Thanks - obviously I'm a beginner on this subject and not medically trained.

In the stroke PR, Kelly is clear about the "macaque model" re leronlimab crossing BBB, citing 70%-75% receptor occupancy in the brain. Is that a trauma situation?

I was musing leronlimab could travel there on the CCR5 receptor of a T-cell, so would only cross in the adverse situations that would let the T-cell cross.

I apologize if the above is nonsense.